Benefits of early use of high-flow-nasal-cannula (HFNC) in patients with COVID-19 associated pneumonia.
INTRODUCTION
Severe COVID-19 is associated with hypoxemic bilateral pneumonia that leads to mechanical ventilation in a considerable proportion of patients. To the best of our knowledge, there are no recommendations about the best time to initiate high flow nasal cannula (HFNC).


PATIENTS AND METHODS
Retrospective study of all patients admitted for COVID-19 pneumonia who required HNFO between March 2020 and February 2021. Patients were grouped in early HNFC or late HNFC, according to the modified Kirby index.


RESULTS
53 patients were included. Forty-four of them were included in the early HFNC and 9 in late HNFC. There were no statistically significant clinical-epidemiological differences. Early use of HFNC was associated with a decrease in the need for intubation (29.5 vs. 66.6%, p = 0.044), hospital stay (18.8 d vs. 36 d, p = 0.022) and mortality (22.7 vs. 55.5%, p = 0.061).


CONCLUSIONS
Early HFNC use is associated with a decrease in the need for intubation, mortality and overall hospital stay.
['García-Pereña|Laura|L|', 'Ramos Sesma|Violeta|V|', 'Tornero Divieso|María Lucía|ML|', 'Lluna Carrascosa|Alfonso|A|', 'Velasco Fuentes|Sara|S|', 'Parra-Ruiz|Jorge|J|']
COVID-19 Pneumonia HNFC Kirby index Neumonía ONAF Índice de Kirby